$NTLA
Intellia Therapeutics, Inc.

2016 Q3 Form 10-Q Financial Statement

#000119312516671974 Filed on August 04, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2016 Q2 2015 Q2
Revenue $4.870M $4.210M $1.380M
YoY Change 188.17% 205.07%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.710M $3.730M $2.830M
YoY Change 207.84% 31.8%
% of Gross Profit
Research & Development $7.861M $7.423M $1.966M
YoY Change 127.33% 277.57%
% of Gross Profit
Depreciation & Amortization $270.0K $240.0K $70.00K
YoY Change 170.0% 242.86%
% of Gross Profit
Operating Expenses $7.861M $7.423M $1.966M
YoY Change 127.33% 277.57%
Operating Profit -$7.697M -$6.946M -$3.422M
YoY Change 133.17% 102.98%
Interest Expense $220.0K $50.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$7.482M -$6.900M -$3.422M
YoY Change 126.66% 101.64%
Income Tax $0.00 $0.00 -$382.0K
% Of Pretax Income
Net Earnings -$7.482M -$6.900M -$3.040M
YoY Change 147.83% 126.97%
Net Earnings / Revenue -153.63% -163.9% -220.29%
Basic Earnings Per Share
Diluted Earnings Per Share -$217.9K -$360.9K -$86.61K
COMMON SHARES
Basic Shares Outstanding 36.00M shares 36.00M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $290.6M $300.7M $19.80M
YoY Change 251.82% 1418.69%
Cash & Equivalents $290.6M $300.7M $19.77M
Short-Term Investments
Other Short-Term Assets $1.000M $1.200M $500.0K
YoY Change 66.67% 140.0%
Inventory
Prepaid Expenses
Receivables $1.112M $1.000M $2.000M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $292.7M $302.9M $22.30M
YoY Change 247.21% 1258.31%
LONG-TERM ASSETS
Property, Plant & Equipment $5.492M $4.421M $1.500M
YoY Change 174.6% 194.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.275M $3.299M $400.0K
YoY Change 118.33% 724.75%
Total Long-Term Assets $8.767M $7.720M $1.900M
YoY Change 157.85% 306.32%
TOTAL ASSETS
Total Short-Term Assets $292.7M $302.9M $22.30M
Total Long-Term Assets $8.767M $7.720M $1.900M
Total Assets $301.5M $310.6M $24.20M
YoY Change 243.75% 1183.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $657.0K $1.042M $1.500M
YoY Change -6.14% -30.53%
Accrued Expenses $4.810M $4.288M $3.100M
YoY Change 45.76% 38.32%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $22.63M $21.62M $10.80M
YoY Change 117.63% 100.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $306.0K $363.0K $6.000M
YoY Change -94.0% -93.95%
Total Long-Term Liabilities $306.0K $363.0K $6.000M
YoY Change -94.0% -93.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.63M $21.62M $10.80M
Total Long-Term Liabilities $306.0K $363.0K $6.000M
Total Liabilities $22.94M $21.98M $16.80M
YoY Change 48.95% 30.83%
SHAREHOLDERS EQUITY
Retained Earnings -$43.01M -$35.53M
YoY Change
Common Stock $261.1M $259.1M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $218.1M $223.6M $7.300M
YoY Change
Total Liabilities & Shareholders Equity $301.5M $310.6M $24.20M
YoY Change 243.75% 1183.57%

Cashflow Statement

Concept 2016 Q3 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$7.482M -$6.900M -$3.040M
YoY Change 147.83% 126.97%
Depreciation, Depletion And Amortization $270.0K $240.0K $70.00K
YoY Change 170.0% 242.86%
Cash From Operating Activities -$7.610M $67.55M $2.180M
YoY Change 132.72% 2998.62%
INVESTING ACTIVITIES
Capital Expenditures -$600.0K -$1.150M -$580.0K
YoY Change -1.64% 98.28%
Acquisitions
YoY Change
Other Investing Activities -$600.0K
YoY Change
Cash From Investing Activities -$600.0K -$1.150M -$1.180M
YoY Change 5900.0% -2.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.860M 170.1M 300.0K
YoY Change -102.81% 56600.0% 200.0%
NET CHANGE
Cash From Operating Activities -7.610M 67.55M 2.180M
Cash From Investing Activities -600.0K -1.150M -1.180M
Cash From Financing Activities -1.860M 170.1M 300.0K
Net Change In Cash -10.07M 236.5M 1.300M
YoY Change -116.03% 18092.31% 1200.0%
FREE CASH FLOW
Cash From Operating Activities -$7.610M $67.55M $2.180M
Capital Expenditures -$600.0K -$1.150M -$580.0K
Free Cash Flow -$7.010M $68.70M $2.760M
YoY Change 163.53% 2389.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35995074 shares
CY2015Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
500000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19765000
CY2016Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1181000
CY2016Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
270051000
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
270051000
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35995074 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35995074 shares
CY2016Q2 us-gaap Assets
Assets
310624000
CY2016Q2 us-gaap Assets Current
AssetsCurrent
302904000
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2016Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
7600000
CY2016Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
259123000
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
300687000
CY2016Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1000000
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
4000
CY2016Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
65042000
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1042000
CY2016Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
16287000
CY2016Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2907000
CY2016Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4288000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
31864000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
4878000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
4736000
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
310624000
CY2016Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
363000
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
21617000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
9786000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
3402000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4598000
CY2016Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3299000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
46615000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
4464000
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4421000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.81
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
223602000
CY2016Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
15100000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.94
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
257 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1764577 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.80
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-35525000
CY2016Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1217000
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2934699 shares
CY2016Q2 ntla Remaining Obligation Acquired In Process Research And Development
RemainingObligationAcquiredInProcessResearchAndDevelopment
200000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9845000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1281000
CY2015Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
30000000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
30000000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2558755 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2558755 shares
CY2015Q4 us-gaap Assets
Assets
82139000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
77626000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
735000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75816000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1000000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3765000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1360000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6547000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
907000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2788000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82139000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
323000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10695000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1805000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2708000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-21201000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.04
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2227276 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.81
CY2015Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
88557000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-21936000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
810000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
456374 shares
CY2015Q4 ntla Remaining Obligation Acquired In Process Research And Development
RemainingObligationAcquiredInProcessResearchAndDevelopment
600000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24051000 shares
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
9920000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
185000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3943000
us-gaap Depreciation
Depreciation
100000
us-gaap Costs And Expenses
CostsAndExpenses
7280000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
600000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
504000
us-gaap Net Income Loss
NetIncomeLoss
-4133000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
4644000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4617000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1103000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
2663000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1197000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6975000
us-gaap Depreciation
Depreciation
434000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Costs And Expenses
CostsAndExpenses
19623000
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
237000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
31000
us-gaap Operating Income Loss
OperatingIncomeLoss
-4617000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
119000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4028000
us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
-484000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
9694000
us-gaap Income Tax Effects Allocated Directly To Equity
IncomeTaxEffectsAllocatedDirectlyToEquity
1000000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-484000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
6995000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1103000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3337000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation
ShareBasedCompensation
266000
ntla Initial Public Offering Costs Incurred But Not Yet Paid
InitialPublicOfferingCostsIncurredButNotYetPaid
13000
ntla Payments Of Temporary Equity Issuance Costs
PaymentsOfTemporaryEquityIssuanceCosts
16000
ntla Earnings Per Common Unit Basic And Diluted
EarningsPerCommonUnitBasicAndDiluted
-3.22
ntla Weighted Average Number Of Common Units Outstanding Basic And Diluted
WeightedAverageNumberOfCommonUnitsOutstandingBasicAndDiluted
1284000 shares
ntla Collaboration Consideration Allocated To Equity
CollaborationConsiderationAllocatedToEquity
2600000
ntla In Process Research And Development Acquired But Not Yet Paid
InProcessResearchAndDevelopmentAcquiredButNotYetPaid
1100000
dei Entity Registrant Name
EntityRegistrantName
INTELLIA THERAPEUTICS, INC.
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4700000 shares
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001652130
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2645000
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
224871000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.37
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
213000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
400000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1053000
us-gaap Net Income Loss
NetIncomeLoss
-13589000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13589000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2155000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
5983000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-367000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
407000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2699000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13640000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
40000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
168897000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
71017000
us-gaap Investment Income Interest
InvestmentIncomeInterest
51000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
58129000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2155000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
170507000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
1.34
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3316000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y7M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
461508 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
1191 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y2M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
0.85
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
167190000
dei Trading Symbol
TradingSymbol
NTLA
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12648000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.879 pure
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1110000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2478325 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.013 pure
us-gaap Share Based Compensation
ShareBasedCompensation
2645000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9899000 shares
ntla Initial Public Offering Costs Incurred But Not Yet Paid
InitialPublicOfferingCostsIncurredButNotYetPaid
1604000
ntla Conversion Of Convertible Preferred Stock Into Common Stock
ConversionOfConvertiblePreferredStockIntoCommonStock
-88557000
ntla Payments Of Temporary Equity Issuance Costs
PaymentsOfTemporaryEquityIssuanceCosts
100000
ntla In Process Research And Development Acquired But Not Yet Paid
InProcessResearchAndDevelopmentAcquiredButNotYetPaid
200000
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24051000 shares
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2833000
CY2015Q2 us-gaap Costs And Expenses
CostsAndExpenses
4799000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-3040000
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3422000
CY2015Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
1377000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3422000
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-382000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1966000
CY2015Q2 us-gaap Share Based Compensation
ShareBasedCompensation
151000
CY2015Q2 ntla Earnings Per Common Unit Basic And Diluted
EarningsPerCommonUnitBasicAndDiluted
-2.37
CY2015Q2 ntla Weighted Average Number Of Common Units Outstanding Basic And Diluted
WeightedAverageNumberOfCommonUnitsOutstandingBasicAndDiluted
1284000 shares
CY2016Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4700000 shares
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3729000
CY2016Q2 us-gaap Costs And Expenses
CostsAndExpenses
11152000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-6900000
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6900000
CY2016Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
4206000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6946000
CY2016Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
46000
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7423000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
13.57
CY2016Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1833000
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19121000 shares

Files In Submission

Name View Source Status
0001193125-16-671974-index-headers.html Edgar Link pending
0001193125-16-671974-index.html Edgar Link pending
0001193125-16-671974.txt Edgar Link pending
0001193125-16-671974-xbrl.zip Edgar Link pending
d190141d10q.htm Edgar Link pending
d190141dex311.htm Edgar Link pending
d190141dex312.htm Edgar Link pending
d190141dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g190141g72x53.jpg Edgar Link pending
ntla-20160630.xml Edgar Link completed
ntla-20160630.xsd Edgar Link pending
ntla-20160630_cal.xml Edgar Link unprocessable
ntla-20160630_def.xml Edgar Link unprocessable
ntla-20160630_lab.xml Edgar Link unprocessable
ntla-20160630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending